Lv4
440 积分 2021-03-22 加入
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
7天前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
7天前
已完结
Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer
11天前
已完结
Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer
11天前
已完结
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
18天前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
18天前
已完结
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer
25天前
已完结
Lung cancer in China: current and prospect
25天前
已完结
Advances in RAS Therapeutics for Pancreatic Cancer
27天前
已关闭
Advances in RAS Therapeutics for Pancreatic Cancer
27天前
已完结
皖公网安备34019202002308
